What is the cost-effectiveness of Mineralocorticoid receptor antagonists versus placebo for chronic heart failure with reduced ejection fraction?
The study found that eplerenone remained cost-effective after undertaking both deterministic and probabilistic sensitivity analysis. Two scenario analyses using EMPHASIS-HF data with no extrapolation and another using only a 2 year time horizon generated ICERs of 20,730 and 20,101 per QALY gained, respectively. In all other scenario analyses eplerenone remained cost-effective.